Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2Leukemia, Promyelocytic, Acute 1

Interventions

Cytarabine 184Cyclophosphamide 176fludarabine 146Azacitidine 121venetoclax 115fludarabine phosphate 104Rituximab 80Decitabine 74Filgrastim 58Specimen Handling 55Etoposide 55Lenalidomide 47Biopsy 45Dexamethasone 41Methotrexate 40Bortezomib 40Mitoxantrone 39Granulocyte Colony-Stimulating Factor 39Daunorubicin 39Vincristine 37Melphalan 36ibrutinib 35Tacrolimus 35Dasatinib 34Whole-Body Irradiation 32Clofarabine 32Peripheral Blood Stem Cell Transplantation 31Mycophenolic Acid 31Injections 31Idarubicin 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × vadastuximab talirine × Other hematologic neoplasm × Clear all
NCT02326584 2018-05-09

A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML

Seagen Inc.

Phase 1 Completed
116 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01902329 2018-01-05

A Safety Study of SGN-CD33A in AML Patients

Seagen Inc.

Phase 1 Completed
195 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡